Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations

Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The international journal of neuropsychopharmacology 2024-02, Vol.27 (2), p.1
Hauptverfasser: Turkoz, Ibrahim, Daskiran, Mehmet, Siddiqui, Uzma, Knight, R Karl, Johnston, Karen L, Correll, Christoph U
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 1
container_title The international journal of neuropsychopharmacology
container_volume 27
creator Turkoz, Ibrahim
Daskiran, Mehmet
Siddiqui, Uzma
Knight, R Karl
Johnston, Karen L
Correll, Christoph U
description Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates with PP6M from an open-label extension (OLE) study in adult patients with schizophrenia. Methods PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind, noninferiority, phase-3 study (NCT03345342) without relapse. Patients in the PP3M and PP1M ECAs were identified from the IBM® MarketScan® Multistate Medicaid Database based on similar eligibility criteria as the PP6M cohort. Results A total of 178 patients were included in each cohort following propensity score matching. Most patients were men (>70%; mean age: 39–41 years). Time to relapse (primary analysis based on Kaplan-Meier estimates) was significantly delayed in the PP6M cohort (P 
doi_str_mv 10.1093/ijnp/pyad067
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2921119462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A788380487</galeid><oup_id>10.1093/ijnp/pyad067</oup_id><sourcerecordid>A788380487</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-f91d9a06fc6b50a72522998df83f71cb6abf46f8deb2baa0838be891cc64e0e93</originalsourceid><addsrcrecordid>eNp9kk2LFDEQhhtR3A-9eZaABz3Yu0l_t7dh3FFhZWVW2WNT3ak4WdJJTNLg7F_1z5h22gVRJIekqp56K1Bvkjxj9IzRNj-Xt9qe2z1wWtUPkmNWVG1aMsYe_nqzlBVlfZSceH9LaVaUefU4OcqbPAZ5eZz82KIC65FsIaAnNzLsyCdQ0qKT3Gicg1GGWCRSkxWfVIipIFGHhb4edvLO2J1DLeEN2aKPjCfCOBJ2SKr0o9ER2xg3Tip2Gk02zowENLmyqFMFPSpy8T2g9nPxOkx8T9ZmtOCQk2CiJKj0xjjFyVsIcC_NFmnQnOR_j_FPkkcClMeny32afNlcfF6_Ty-v3n1Yry7TIW_KkIqW8RZoJYaqLynUWZllbdtw0eSiZkNfQS-KSjQc-6wHoE3e9Ni0bBiqAim2-Wny6qBrnfk2oQ_dKP2ASoFGM_kua7O4j7aosoi-OKBfQWEntTDBwTDj3apuojItmjpSZ_-g4uE4yiFuRciY_6Ph9aFhcMZ7h6KzTo7g9h2j3eySbnZJt7gk4s-XD0_9iPwe_m2LCLw8AGay_5f6CY5hyes</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2921119462</pqid></control><display><type>article</type><title>Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Turkoz, Ibrahim ; Daskiran, Mehmet ; Siddiqui, Uzma ; Knight, R Karl ; Johnston, Karen L ; Correll, Christoph U</creator><creatorcontrib>Turkoz, Ibrahim ; Daskiran, Mehmet ; Siddiqui, Uzma ; Knight, R Karl ; Johnston, Karen L ; Correll, Christoph U</creatorcontrib><description>Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates with PP6M from an open-label extension (OLE) study in adult patients with schizophrenia. Methods PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind, noninferiority, phase-3 study (NCT03345342) without relapse. Patients in the PP3M and PP1M ECAs were identified from the IBM® MarketScan® Multistate Medicaid Database based on similar eligibility criteria as the PP6M cohort. Results A total of 178 patients were included in each cohort following propensity score matching. Most patients were men (&gt;70%; mean age: 39–41 years). Time to relapse (primary analysis based on Kaplan-Meier estimates) was significantly delayed in the PP6M cohort (P &lt; .001, log-rank test). The relapse rate was lower in the PP6M cohort (3.9%) vs PP3M (20.2%) and PP1M (29.8%) cohorts. Risk of relapse decreased significantly (P &lt; .001) by 82% for PP6M vs PP3M (HR = 0.18 [95% CI = 0.08 to 0.40]), 89% for PP6M vs PP1M (HR = 0.11 [0.05 to 0.25]), and 35% for PP3M vs PP1M (HR = 0.65 [0.42 to 0.99]; P = .043). Sensitivity analysis confirmed findings from the primary analysis. Although the ECAs were matched to mimic the characteristics of the PP6M cohort, heterogeneity between the groups could exist due to factors including prior study participation, unmeasured confounders, variations in data capture and quality, and completeness of clinical information. Conclusions In a clinical trial setting, PP6M significantly delayed time to relapse and demonstrated lower relapse rates compared with PP3M and PP1M treatments in real-world settings among adult patients with schizophrenia. Trial registration ClinicalTrials.gov Identifier: NCT04072575; EudraCT number: 2018-004532-30</description><identifier>ISSN: 1461-1457</identifier><identifier>EISSN: 1469-5111</identifier><identifier>DOI: 10.1093/ijnp/pyad067</identifier><identifier>PMID: 38300235</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>The international journal of neuropsychopharmacology, 2024-02, Vol.27 (2), p.1</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of CINP. 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press on behalf of CINP.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c385t-f91d9a06fc6b50a72522998df83f71cb6abf46f8deb2baa0838be891cc64e0e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38300235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turkoz, Ibrahim</creatorcontrib><creatorcontrib>Daskiran, Mehmet</creatorcontrib><creatorcontrib>Siddiqui, Uzma</creatorcontrib><creatorcontrib>Knight, R Karl</creatorcontrib><creatorcontrib>Johnston, Karen L</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><title>Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations</title><title>The international journal of neuropsychopharmacology</title><addtitle>Int J Neuropsychopharmacol</addtitle><description>Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates with PP6M from an open-label extension (OLE) study in adult patients with schizophrenia. Methods PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind, noninferiority, phase-3 study (NCT03345342) without relapse. Patients in the PP3M and PP1M ECAs were identified from the IBM® MarketScan® Multistate Medicaid Database based on similar eligibility criteria as the PP6M cohort. Results A total of 178 patients were included in each cohort following propensity score matching. Most patients were men (&gt;70%; mean age: 39–41 years). Time to relapse (primary analysis based on Kaplan-Meier estimates) was significantly delayed in the PP6M cohort (P &lt; .001, log-rank test). The relapse rate was lower in the PP6M cohort (3.9%) vs PP3M (20.2%) and PP1M (29.8%) cohorts. Risk of relapse decreased significantly (P &lt; .001) by 82% for PP6M vs PP3M (HR = 0.18 [95% CI = 0.08 to 0.40]), 89% for PP6M vs PP1M (HR = 0.11 [0.05 to 0.25]), and 35% for PP3M vs PP1M (HR = 0.65 [0.42 to 0.99]; P = .043). Sensitivity analysis confirmed findings from the primary analysis. Although the ECAs were matched to mimic the characteristics of the PP6M cohort, heterogeneity between the groups could exist due to factors including prior study participation, unmeasured confounders, variations in data capture and quality, and completeness of clinical information. Conclusions In a clinical trial setting, PP6M significantly delayed time to relapse and demonstrated lower relapse rates compared with PP3M and PP1M treatments in real-world settings among adult patients with schizophrenia. Trial registration ClinicalTrials.gov Identifier: NCT04072575; EudraCT number: 2018-004532-30</description><issn>1461-1457</issn><issn>1469-5111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kk2LFDEQhhtR3A-9eZaABz3Yu0l_t7dh3FFhZWVW2WNT3ak4WdJJTNLg7F_1z5h22gVRJIekqp56K1Bvkjxj9IzRNj-Xt9qe2z1wWtUPkmNWVG1aMsYe_nqzlBVlfZSceH9LaVaUefU4OcqbPAZ5eZz82KIC65FsIaAnNzLsyCdQ0qKT3Gicg1GGWCRSkxWfVIipIFGHhb4edvLO2J1DLeEN2aKPjCfCOBJ2SKr0o9ER2xg3Tip2Gk02zowENLmyqFMFPSpy8T2g9nPxOkx8T9ZmtOCQk2CiJKj0xjjFyVsIcC_NFmnQnOR_j_FPkkcClMeny32afNlcfF6_Ty-v3n1Yry7TIW_KkIqW8RZoJYaqLynUWZllbdtw0eSiZkNfQS-KSjQc-6wHoE3e9Ni0bBiqAim2-Wny6qBrnfk2oQ_dKP2ASoFGM_kua7O4j7aosoi-OKBfQWEntTDBwTDj3apuojItmjpSZ_-g4uE4yiFuRciY_6Ph9aFhcMZ7h6KzTo7g9h2j3eySbnZJt7gk4s-XD0_9iPwe_m2LCLw8AGay_5f6CY5hyes</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Turkoz, Ibrahim</creator><creator>Daskiran, Mehmet</creator><creator>Siddiqui, Uzma</creator><creator>Knight, R Karl</creator><creator>Johnston, Karen L</creator><creator>Correll, Christoph U</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240201</creationdate><title>Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations</title><author>Turkoz, Ibrahim ; Daskiran, Mehmet ; Siddiqui, Uzma ; Knight, R Karl ; Johnston, Karen L ; Correll, Christoph U</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-f91d9a06fc6b50a72522998df83f71cb6abf46f8deb2baa0838be891cc64e0e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turkoz, Ibrahim</creatorcontrib><creatorcontrib>Daskiran, Mehmet</creatorcontrib><creatorcontrib>Siddiqui, Uzma</creatorcontrib><creatorcontrib>Knight, R Karl</creatorcontrib><creatorcontrib>Johnston, Karen L</creatorcontrib><creatorcontrib>Correll, Christoph U</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The international journal of neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turkoz, Ibrahim</au><au>Daskiran, Mehmet</au><au>Siddiqui, Uzma</au><au>Knight, R Karl</au><au>Johnston, Karen L</au><au>Correll, Christoph U</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations</atitle><jtitle>The international journal of neuropsychopharmacology</jtitle><addtitle>Int J Neuropsychopharmacol</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>27</volume><issue>2</issue><spage>1</spage><pages>1-</pages><issn>1461-1457</issn><eissn>1469-5111</eissn><abstract>Abstract Background The 3 paliperidone palmitate (PP) long-acting injectable antipsychotic formulations, PP 1-month (PP1M), PP 3-month (PP3M), and PP 6-month (PP6M), have shown to reduce the risk of relapse in schizophrenia. The current phase-4 study constructed external comparator arms (ECAs) using real-world data for PP3M and PP1M and compared relapse prevention rates with PP6M from an open-label extension (OLE) study in adult patients with schizophrenia. Methods PP6M data were derived from a single-arm, 24-month, OLE study (NCT04072575), which included patients with schizophrenia who completed a 12-month randomized, double-blind, noninferiority, phase-3 study (NCT03345342) without relapse. Patients in the PP3M and PP1M ECAs were identified from the IBM® MarketScan® Multistate Medicaid Database based on similar eligibility criteria as the PP6M cohort. Results A total of 178 patients were included in each cohort following propensity score matching. Most patients were men (&gt;70%; mean age: 39–41 years). Time to relapse (primary analysis based on Kaplan-Meier estimates) was significantly delayed in the PP6M cohort (P &lt; .001, log-rank test). The relapse rate was lower in the PP6M cohort (3.9%) vs PP3M (20.2%) and PP1M (29.8%) cohorts. Risk of relapse decreased significantly (P &lt; .001) by 82% for PP6M vs PP3M (HR = 0.18 [95% CI = 0.08 to 0.40]), 89% for PP6M vs PP1M (HR = 0.11 [0.05 to 0.25]), and 35% for PP3M vs PP1M (HR = 0.65 [0.42 to 0.99]; P = .043). Sensitivity analysis confirmed findings from the primary analysis. Although the ECAs were matched to mimic the characteristics of the PP6M cohort, heterogeneity between the groups could exist due to factors including prior study participation, unmeasured confounders, variations in data capture and quality, and completeness of clinical information. Conclusions In a clinical trial setting, PP6M significantly delayed time to relapse and demonstrated lower relapse rates compared with PP3M and PP1M treatments in real-world settings among adult patients with schizophrenia. Trial registration ClinicalTrials.gov Identifier: NCT04072575; EudraCT number: 2018-004532-30</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>38300235</pmid><doi>10.1093/ijnp/pyad067</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1461-1457
ispartof The international journal of neuropsychopharmacology, 2024-02, Vol.27 (2), p.1
issn 1461-1457
1469-5111
language eng
recordid cdi_proquest_miscellaneous_2921119462
source DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
title Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A40%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapse%20Rates%20With%20Paliperidone%20Palmitate%20in%20Adult%20Patients%20With%20Schizophrenia:%20Results%20for%20the%206-Month%20Formulation%20From%20an%20Open-label%20Extension%20Study%20Compared%20to%20Real-World%20Data%20for%20the%201-Month%20and%203-Month%20Formulations&rft.jtitle=The%20international%20journal%20of%20neuropsychopharmacology&rft.au=Turkoz,%20Ibrahim&rft.date=2024-02-01&rft.volume=27&rft.issue=2&rft.spage=1&rft.pages=1-&rft.issn=1461-1457&rft.eissn=1469-5111&rft_id=info:doi/10.1093/ijnp/pyad067&rft_dat=%3Cgale_proqu%3EA788380487%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2921119462&rft_id=info:pmid/38300235&rft_galeid=A788380487&rft_oup_id=10.1093/ijnp/pyad067&rfr_iscdi=true